Bringing the fundamentals into focus…
Back to 4D Molecular Therapeutics, Inc.
How 4D Molecular Therapeutics, Inc. stacks up
FDMT · against 1,216 other Healthcare companies
Growth
96/ 100
Near the top of its peers.
Ranked #39 of 1,217 · scores higher than 96% of peers
Bars: peers in each 10-point band of the growth score128 peers with a growth score of 90–100, including FDMT · Click a bar to see the companies
Why growth scores 96?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its revenue growth and 3-year revenue growth, which are stronger than most Healthcare peers.
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
- faster revenue growth over three years: stronger than 99% of peers. 3-year revenue growth: 242.8% vs peer median 5.8%
- faster revenue growth over the last year: stronger than 100% of peers. Revenue growth: 278712.1% vs peer median 6.1%
Metric by metric
Position: dot = FDMT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | FDMT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 1,243 reported | 278712.1% | 6.1% | 100% | 33% | |
| Earnings per share growthHigher is better · 682 reported | Not reported | 9.7% | — | — | 33% |
| 3-year revenue growthHigher is better · 1,192 reported | 242.8% | 5.8% | 99% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around FDMT| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 464M USD | 100 | 53 | |
| 3 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 3 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 3 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 39 | 14.5B USD | 96 | 30 | |
| 39 | 5.7B USD | 96 | 52 | |
| 39 | 500M USD | 96 | 63 | |
| 39 | 1.5B USD | 96 | 63 | |
| 39 | 660M USD | 96 | 43 | |
| 39 | 598M USD | 96 | 49 | |
| 39 | 1.2B CHF (≈$1.3B) | 96 | 28 | |
| 39 | 275M USD | 96 | 46 | |
| 39 | 1.9B USD | 96 | 44 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score